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ABSTRACT	  
IL-1β Amplification of Nitric Oxide Production and Its Inhibitory Effects on Glucose Induced 
Early Growth Response-1 Expression in INS-1 Cells 	  by	  Ada	  Young	  
The pathophysiology of cytokines released by infiltrating white blood cells upon pancreatic beta 
cells is not fully understood. Early growth response gene-1 (Egr-1) expression is specifically and 
transiently up regulated in pancreatic beta cells in response to glucose. We hypothesized that 
interleukin-1 beta (IL-1β) induction of nitric oxide alters glucose induced Egr-1 transcription 
levels. Egr-1 levels were assessed via western blot, nitric oxide was measured with a Griess 
Reagent kit and insulin levels via ELISA. Glucose induced both insulin and Egr-1 production in 
INS-1 cells. IL-1β dose dependently increased nitric oxide production over time and 
significantly attenuated glucose induced Egr-1 expression. Sodium nitroprusside dose 
dependently reduced glucose induced Egr-1 production. The data suggest a strong relationship 
between IL-1β induced nitric oxide production and the reduction of glucose stimulated Egr-1 
production. The pathways altered by this cytokine could provide a better understanding of the 
pathophysiology leading to pancreatic beta cell death. 
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CHAPTER 1 
 
INTRODUCTION 
 
The pancreas is a glandular organ that is intricately involved in the gastrointestinal 
digestive process. It regulates the uptake of carbohydrates, lipids, and proteins by releasing 
insulin to bind to specific insulin responsive tissues (Boron and Boulpaep 2003). The major 
targets of insulin include liver, muscle, and adipose tissue (Nussey and Whithead 2001). The 
regulation of metabolism through the pancreas occurs via the binding of specific 
neurotransmitters by the exocrine gland cells and glucose by the endocrine gland cells, 
respectively (Boron and Boulpaep 2003). The endocrine portion of the pancreas contains beta 
cells found within the islets of Langerhans. Increased blood glucose stimulates the pancreatic 
beta cells to synthesize and secrete insulin into the blood stream (Boron and Boulpaep 2003). 
Once in circulation, insulin binds to specific target tissues, making them more receptive to 
glucose uptake (Nussey and Whithead 2001). Insulin also acts in an autocrine and paracrine 
fashion, binding to the beta cells it is released from and/or adjacent beta cells (Boron and 
Boulpaep 2003). It is the flux of islet beta cell binding to glucose and insulin that regulates 
insulin production and secretion within the pancreas. 
 
Receptors specific for glucose (ex. GLUT 2) can bind and passively transport the sugar 
molecules into the cell depending upon the concentration gradient between the inside and the 
outside of the cell. Once glucose enters the cell, a key enzyme, glucokinase, initiates the process 
of glycolysis. This metabolic process affects production and secretion of insulin (Ashcroft 1980; 
German 1993). Oxidative glucose metabolism increases ATP within the cell, closing ATP 
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sensitive potassium channels leading to cellular depolarization via calcium influx (Figure 1.1). 
The increased concentration of cytosolic calcium is a very important component in the glucose-
stimulated exocytosis of insulin granules (Szollosl et al. 2007). The breakdown of glucose for 
energy and the influx of calcium alter the concentrations of a number of key regulatory enzymes 
and in turn activate pathways that help promote insulin production and release and overall beta 
cell health. It is critical to the health of the pancreas and the organism as a whole for these 
pathways and molecules to interact in a balanced and consistent manner. A disruption or 
imbalance can lead to beta cell dysfunction and even affect the use of glucose throughout the 
body.  
 
 
Figure 1.1 – Schematic model of glucose stimulated insulin production and exocytosis in a 
healthy pancreatic β cell (Adapted from Gottlob et al. 2001; Srinivasan et al. 2002; Szollosl et al. 
2007). 
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Development of Insulin Dependent Diabetes Mellitus 
 
Insulin-dependent diabetes mellitus (IDDM or Type 1 diabetes) is one of the most 
frequent chronic childhood diseases with a prevalence estimated to affect approximately 120,000 
individuals less than 19 years-of-age and 300,000 to 500,000 individuals of all ages (LaPorte et 
al. 1995). The risk of devastating complications associated with this disease remain high and 
include such things as heart disease, stroke, high blood pressure, blindness, kidney disease, 
amputations, etc. Although great strides have been made towards understanding the pathogenesis 
of IDDM, therapies for its prevention have remained elusive. 
Insulin-dependent diabetes mellitus is a macrophage-dependent, T Cell-mediated 
autoimmune disease characterized by the infiltration of the islet cells of the pancreas by immune 
cells (insulitis) followed by massive destruction of insulin-producing pancreatic beta cells. 
Mediation of islet beta cell destruction involves the participation of a variety of 
immune/inflammatory cells in the insulitis lesion, notably dendritic cells, macrophages and T 
lymphocytes, as well as cytokines produced by these cells (Thomas et al. 2000; Yoon and Jun. 
2005; Lehuen et al. 2010). It is believed that the autoimmune response in IDDM involves some 
disturbance(s) in the immunoregulatory balance that leads to a dominance of Th1 cells and their 
respective cytokine production (Thivolet. 2002; La Torre et al. 2010; Lehuen et al. 2010). 
 
Role of Macrophages and IL-12 Production in the Development of IDDM 
 
  A large body of evidence has been produced suggesting macrophages are a key part of 
the initial steps in the development of IDDM (Lee et al. 1988; Yoon and Jun. 1999; Alleva et al. 
2000; Lehuen et al. 2010). Much of this evidence has been obtained through the use of mouse 
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and rat models. BioBreeding (BB) rats and nonobese diabetic (NOD) mice have been used 
extensively in this area of research due to their spontaneous development of autoimmune type 1 
diabetes. It has been found in both BB rats and in NOD mice that macrophages infiltrate the 
pancreas during the initial phase of insulitis (Karges et al. 1995; Lehuen et al. 2010). The 
recruitment of auto-reactive T-cells is dependent upon the activated macrophages and is 
necessary for the development of the disease (Jun et al. 1999; Lehuen et al. 2010). The 
pertinence of macrophages in the development of diabetes has been reproduced in a number of 
other studies and is thought to be accomplished through cytokine signaling between the T-helper 
cells (Th), macrophages, and beta cells (Karges et al. 1995; Jun et al. 1999; Thomas et al. 2000; 
Yoon and Jun. 2005; Eizirik et al. 2009; Lehuen et al. 2010).  
The balance of Th1/Th2 cell populations has been observed to be an important factor in 
the development of immune dysfunction (Delovitch et al. 1997). The cytokine IL-12, released by 
macrophages is understood to be a key regulator in the promotion of Th1 development and has 
been found to be expressed at high levels in NOD mice macrophages (Alleva et al. 2000). Jun et 
al. (1999) found that macrophage depleted NOD mice had lower IL-12 expression which 
prevented diabetes from developing. When they added IL-12 back into the macrophage depleted 
NOD mice, they found a drastic increase in diabetes development. IL-12 has not only been found 
to stimulate Th1 activation but it has also been found to cause direct damage to beta cells 
(Lehuen et al. 2010). Based on these and other findings, it appears that the essential role of 
macrophages in the development of IDDM was due, in part, to their production of IL-12.   
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Role of Immune Cell Cytokine Signaling in the Development of IDDM 
 
A substantial amount of evidence from studies using BB rats and NOD mice supports a 
critical role for T cells and macrophages in the development of IDDM (Rabinovitch and Suarez-
Pinzon. 1998; Jun et al. 1999; Yoon et al. 2005; Leheun et al. 2010). Insulitis is characterized by 
leukocyte infiltration of the pancreatic islets by a mixture of CD4+ and CD8+ lymphocytes, B-
lymphocytes, macrophages, and dendritic cells in NOD mice and humans recently diagnosed 
with IDDM (Thomas et al. 2000; Yoon and Jun. 2005; Lehuen et al. 2010). As was previously 
described, macrophage secretion of IL-12 directs T helper cells to differentiate along the Th1 
pathway and stimulates the production of a variety of proinflammatory (IL-1ß and TNFα) and 
Th1 cytokines (IL-2 and IFN-γ) (Jun et al. 1999; Alleva et al. 2000; Yoon and Jun. 2005).  The 
potential role of these proinflammatory and Th1 cytokines in the development of diabetes has 
been the primary focus of numerous research studies over the past few decades (Jun et al. 1999; 
Alleva et al. 2000; Thomas et al. 2000; Yoon and Jun. 2005; Lehuen et al. 2010). 
Activation of CD4+T cells and CD8+T cells to pancreatic autoantigens is induced by the 
binding of macrophages and dendritic cells and their consequential release of IL-12 (Yoon and 
Jun. 2005). Macrophage activated Th1 cells release cytokines, including IL-2, which signal white 
blood cells to migrate and respond to pancreatic beta cells (Rabinovitch and Suarez-Pinzon 
1998). CD4+ T cells release IFNγ, acting in a cyclical fashion, inducing macrophages to become 
cytotoxic (Yoon and Jun 2005). The combined release of IFNγ by T-cells and cytotoxic 
macrophages activates other resting macrophages (Yoon et al. 1998). The large population of 
cytotoxic macrophages and active dendritic cells then release a series of detrimental cytokines to 
the beta cells including interleukin-1beta (IL-1β), Tumor Necrosis Factor (TNF), and free 
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radicals (Uno et al. 2007). A number of studies have found IL-1β and TNF damage islet cells 
and induce apoptosis (Thomas et al. 2000; Yoon and Jun. 2005; Uno et al. 2007; Schwarznau et 
al. 2009). 
Tumor Necrosis Factor is a cytokine mainly produced by macrophages and T-helper 
cells. Green et al. (1998) found that the expression of TNFα in the beta cells of neonatal NOD 
mice caused diabetes development in all mice. Kagi et al. (1999) produced a TNFR-1 deficient 
NOD mouse model that developed insulitis but not diabetes. Studies have found TNFα 
combined with IFNγ are very important factors in the destruction of beta cells and have often 
been studied in congruence with a macrophage-derived cytokine, IL-1β (Campbell et al. 1988; 
Suk et al. 2001; Wachlin et al. 2003; Kim et al. 2007). Cumulatively, these findings support the 
involvement of many immune cells and their respective cytokines in the pathogenesis of IDDM. 
They support the concept posed by Rabinovitch (1998) and many other researchers that the 
deletion of a single “pathogenic” cytokine is not likely to be sufficient for complete prevention 
of diabetes. 	  
 
Interleukin 1-beta (IL-1β) Induces Nitric Oxide Production 
 
The cytokine IL-1β is released by macrophages and pancreatic beta cells depending upon 
the type of stress the cells are under (Maedler et al. 2002; Donath et al. 2010; Venieratos et al. 
2010). Once bound to the cell, IL-1β in high doses activates pathways leading to cell dysfunction 
and eventually to apoptosis. Nuclear factor kappa B (NfкB), a ubiquitous transcription activator, 
is activated by glucose and IL-1ß. Activation of NF-ĸB via IL-1ß alters its role, inducing beta 
cell apoptosis (Eldor et al. 2006; Ortis et al. 2008). The damage and eventual death of the beta 
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cell is in part due to the activation of iNOS and production of the reactive oxygen species NO via 
activation of NF-kB (Evans et al. 2003; Aktan 2004). Chen et al. (2000) found when selecting 
for INS-1 cells resistant against IL-1β that the cells had a disruption in the NF-kB/iNOS 
pathway. Eldor et al. (2006) found with the use of a transgenic mouse model expressing a 
degradation resistant NFкB protein inhibitor that the effects of cytokine attack could be 
prevented. The negative effect of IL-1β on healthy pancreatic beta cell pathways has been 
reported to affect the PI3/Akt pathway as well (Aikin et al. 2004; Elghazi et al. 2006; Martinez et 
al. 2006). 
The enzyme Phosphoinositide 3-kinase and one of its main targets, protein kinase B 
(Akt), are known to be directly affected by glucose and IL-1ß in beta cells (Elghazi et al. 2006; 
Martinez et al. 2006). Increased expression of this kinase participates in beta cell survival 
through inhibition of the JNK pathway, a stress responsive pathway (Aikin et al. 2004; Elghazi et 
al. 2006). Aikin et al. (2004) also found inhibition of PI3K made beta cells more susceptible to 
cytokine mediated death. The reduction of Akt/PKB activity has been shown to exhibit defective 
insulin secretion but normal beta cell mass (Bernal-Mizrachi et al. 2004). When the islet cells are 
bound by IL-1β, the JNK pathway is up regulated as are the reactive nitrogen species produced 
by that pathway (Kang et al. 2009; Schwarznau et al. 2009). One of the more notorious and 
detrimental effects of IL-1β and the pathways it alters is the up regulation of inducible nitric 
oxide synthase (iNOS) and thus nitric oxide (NO) production, inhibiting mitochondrial glucose 
oxidation (Ortis et al. 2008, Ortis et al. 2010). 
The reactive nitrogen species produced by IL-1β are known to be a major inducer of 
pancreatic beta cell apoptosis (Eckhardt et al. 1999; Eldor 2006; Friberg et al. 2010). The 
enzyme iNOS, once up-regulated by this cytokine and related MAPKs, produces nitric oxide 
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(NO) leading to beta cell dysfunction (Larsen et al. 1998; Eckhardt et al. 1999). Nitric oxide is so 
detrimental because it reacts with prosthetic groups such as those found in transcription factors, 
structures in DNA, and other proteins (Bogdan. 2001). Adaptability to nitric oxide imbalance 
along with other causes of beta cell dysfunction has provoked the investigation of transcription 
factors affected by cytokine and anti-oxidant pathways (Henderson et al. 1994; Kronke et al. 
2011). 
 
Role of Egr-1 in the Pancreatic Beta Cell 
 
The effect of cytokines and other compounds on beta cells in IDDM directly influences 
transcription factors and the products they create, including insulin. Early growth response 1 
(Egr-1) is a ubiquitous, zinc-finger, transcription factor activated by many pathways and is 
therefore involved in a number of disease states (Pagel & Deindl. 2011). The role of Egr-1 in 
pancreatic beta cells has not been fully discerned. Based upon current research, it appears to have 
a role in protecting beta cells and promoting cell viability in part through insulin production 
(Josefsen et al. 1999; Eto et al. 2006; Kang et al. 2009; Chang et al. 2011).  
Eto et al. (2006) found that varying levels of Egr-1 expression regulated insulin promoter 
activity by controlling another transcription factor, PDX-1. Complimenting this study, Muller et 
al, 2012 found that a doxycycline induced, Egr-1 double negative mouse model had significantly 
decreased expression levels of PDX-1 and insulin mRNA compared to controls.  Garnett et al. 
(2005) silenced Egr-1 activity with small interfering RNA (siRNA) in INS-1 cells and also found 
that glucose stimulation of insulin was not affected. Beta cell proliferation, however, was 
inhibited in a glucose-independent manner. Recent studies focusing on anti-oxidant compounds 
and beta cells have shown that Egr-1 is expressed and activates the transcription of γ-
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glutamylcysteine ligase (GCLC), a rate-limiting enzyme for glutathione (GSH) (Kang et al. 
2009; Chang et al. 2011). Upregulation of GSH was found to protect the beta cell from NO 
damage in INS-1 cells (Kang et al. 2009). These studies suggest Egr-1 plays an integral role in 
the protection and health of pancreatic beta cells.  
Proinflammatory cytokines released by immune cells drastically alter the pathways found 
in normal, healthy pancreatic beta cells (Gurzov et al. 2008; Eizirik et al. 2009; Grunnet et al. 
2009).  The release of IL-1β by macrophages induces the JNK pathway eventually leading to the 
upregulation of iNOS and NO production (Storling et al. 2005). Rabinovitch et al. (1996) 
determined both IL-1β and IFNγ in part promote diabetes development through increasing iNOS 
expression. Henderson et al. (1994) found increased levels of NO reduced Egr-1 expression 
levels in rat lung macrophages. Kronke et al. (2001) further supported the Henderson et al. 
(1994) observation. They treated Sp1 and Egr-1 with a NO donor, s-nitrosocysteine, and found 
that it dose-dependently inhibited DNA binding. The increase of nitric oxide is just one of many 
altered components when beta cells are affronted by cytokines (Figure 1.2). Glucose is a very 
important component that binds beta cells and also has a strong effect on Egr-1 expression 
(Figure 1.2). 	   Josefsen	  et	  al.	  (1999)	  found	  that	  glucose	  dose	  dependently	  stimulated	  Egr-­‐1	  expression	  strongly	  in	  glucose	  responsive	  cell	  lines	  MIN6,	  INS-­‐1,	  and	  βTC-­‐3,	  weakly	  in	  RINm5F	  cells,	  and	  not	  at	  all	  in	  HIT-­‐T15	  hamster	  beta	  cells.	  Egr-1 is a transcription factor 
regulated by its level of expression rather than by cellular location (Kang et al. 2007).	  Induction 
of Egr-1 via glucose appears to be regulated by calcium levels, c-AMP levels, ternary complex 
factors, and kinases all induced by glucose binding (Frodin et al. 1995; Bernal-Mizrachi et al. 
2001; Mayer et al. 2009). Mayer et al. (2009) determined Ca2+, PKC and activation ERK, a 
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kinase, are integral to glucoses ability to upregulate Egr-1 expression. These studies and many 
others suggest Egr-1 plays an important part in beta cell function that is yet to be fully 
understood (Figure 1.2). Attaining a fundamental comprehension of how Egr-1 is affected by 
positive and negative compounds binding the beta cell could lead to a more clear understanding 
of how IDDM develops. 
 
Figure 1.2 – Schematic model of pathways induced by IL-1β and Glucose affecting Egr-1. 
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CHAPTER 2 
 
PRETREATMENT OF INS-1 CELLS WITH IL-1B INHIBITS GLUCOSE-STIMULATED 
EXPRESSION OF EGR-1. 	  	  	  	  	  	  	  	  	   Ada	  Young,	  W.	  Keith	  De	  Ponti,	  John	  J.	  Laffan,	  	  Chaunfu	  Li,	  Leonard	  Robertson,	  and	  Kevin	  F.	  Breuel	  	  
 
 
 
 
 
 
 
 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  
Keywords: egr-1, glucose stimulation, interleukin- 1β 
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ABSTRACT 	  
Objective: Inflammatory Early growth response gene-1 (Egr-1) expression is specifically and 
transiently upregulated in pancreatic beta cells in response to glucose. It has been suggested that 
genes transcriptionally regulated by Egr-1 may be important in normal beta cell function. 
Recently, we reported that interleukin-1β (IL-1β) stimulates Egr-1 expression in pancreatic beta 
cells and that co-administration of sodium nitroprusside, a nitric oxide donor, inhibits the IL-1β-
stimulated increase in Egr-1. The objective of this study was to determine if pre-treatment of beta 
cells with IL-1β alters the ability of glucose to stimulate Egr-1 expression.  
Research Design and Methods: Rat insulinoma cells (INS-1) were cultured for 24 hours in 
glucose free RPMI 1640 media supplemented with fetal calf serum, L-glutamine, antibiotics, 
sodium pyruvate and 2-β-mercaptoethanol (GFCM). In experiment 1, INS-1 cells were treated 
with GFCM alone or GFCM supplemented with 20 mM glucose, 1 mM IBMX and 1 µM 
forskolin and cultured for 0, 30, 60 and 120 minutes. After culture, media and cells were 
collected and stored for subsequent determination of insulin levels and Egr-1 protein expression, 
respectively. In experiment 2, cells were treated with GFCM alone or GFCM supplemented with 
100 U/ml of IL-1β. After 24 hours, media was aspirated and replaced with GFCM alone or 
GFCM supplemented with 20 mM glucose, 1 mM IBMX and 1 µM forskolin. After culture for 2 
hours, cells were collected and stored for subsequent analysis of Egr-1 protein expression by 
western blot.  
Results: In experiment 1, administration of glucose significantly (P<0.05) increased insulin 
levels at 60 (36.9 ng/ml) and 120 (51.6 ng/ml) minutes over that observed at time 0 (7.5 ng/ml). 
Additionally, glucose treatment for 60 and 120 minutes significantly increased (P<0.05) Egr-1 
protein expression in INS-1 cells as compared to those treated with GFCM alone. In experiment 
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2, administration of glucose resulted in a 55 fold increase in Egr-1 protein expression as 
compared to control levels. Pre-treatment with IL-1β completely inhibited (P<0.01) the glucose-
stimulated increase in Egr-1 protein expression.  
Conclusions: Based on these results we speculate that IL-1β stimulation of nitric oxide and the 
subsequent inhibition of glucose stimulated Egr-1 expression is detrimental to normal pancreatic 
beta cell function. 
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Introduction 
Insulin-dependent diabetes mellitus (IDDM) is a macrophage-dependent, T cell-mediated 
autoimmune disease characterized by the infiltration of the islet cells of the pancreas by immune 
cells (insulitis) followed by massive destruction of insulin-producing pancreatic beta cells (Bach 
1994). It is now generally accepted that pro-inflammatory and Th1 cytokines play a key role in 
the destruction of the beta cells. Interleukin-1β (IL-1β) initiates a cascade of events that leads to 
the activation of inducible nitric oxide synthase, the production of nitric oxide (NO) and the 
subsequent destruction of the pancreatic beta cells by an apoptotic process (Corbet & McDaniel 
1996; McDaniel et al. 1997). In addition, the administration of IL-1β inhibits glucose-stimulated 
insulin secretion from rat islets (Hughes et al. 1990).  
A major part of normal pancreatic beta cell function is the binding of glucose and the 
subsequent stimulation of insulin production and secretion.  In order to induce insulin 
production, glucose must activate a series of transcription factors. Specifically, glucose has been 
reported to induce the expression of early growth response gene (Egr-1) (Josefsen et al. 1999).  
Changes in Egr-1 expression levels regulate other beta cell specific transcription factors 
including the pancreas duodenum homeobox-1(PDX-1) and therefore insulin production (Eto et 
al. 2006).   The role of glucose stimulated Egr-1 expression and its effect upon insulin production 
could play a very important part in understanding the development of IDDM.   
 During its development, a series of cytokines and chemokines are released by white 
blood cells.  Interleukin (IL) 1β is one of the cytokines released by macrophages in IDDM 
development and is known to be a direct contributor to the induction of pancreatic β cell death.  
It regulates a number of transcription factors including nuclear factor (NF)-кB and AP-1 (Cahill 
and Rogers 2008; Liu and Khachigian. 2009).  In human and rat aortic smooth muscle cells, IL-
	   22	  
1β has been reported to stimulate histone 3 acetylation and phosphorylation at the Egr-1 
promoter site (Wang et al. 2010).  IL-1β activation of the inhibitor of DNA binding proteins is 
directly mediated by Egr-1 binding in vascular smooth muscle cells (Zhu et al. 2007).  IL-1β also 
induces iNOS and thus nitric oxide production in rodent beta cells.  In glomerular mesangial 
cells, nitric oxide has been found to inhibit growth through impairing Egr-1 function (Rupprecht 
et al. 2000). Further elucidation of the IL-1β and Egr-1 relationship could greatly benefit 
understanding the process and thus the prevention of apoptosis in pancreatic β cells.  
 The role of glucose and IL-1β binding of the pancreatic β cell appear to affect each 
other’s behavior in beta cells.  Glucose metabolism is a normal part of beta cell function and is 
generally believed to assist in the promotion of beta cell survival.  IL-1β is a cytokine that 
mediates abnormal beta cell function and generally assists in the progression of beta cell death.  
Each of these molecules enacts similar pathways and both regulate Egr-1 expression.  The role of 
Egr-1during the development of IDDM, when both glucose and IL-1β are bound to the 
pancreatic beta cell, is not fully understood. Herein, we demonstrate that IL-1β stimulated nitric 
oxide production does inhibit glucose induced Egr-1 expression. 	  
Research Design and Methods 
 
 
Cell Culture 
 
  The rat insulinoma cell line INS-1 used in this work was obtained from Dr. Phillipe 
Halban. Cells were grown in continuous culture in 175-cm2 flasks containing RPMI 1640 
medium supplemented with 10% inactivated fetal calf serum, 2 ,mM L-glutamine, 1 mM 
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pyruvate, 50 µM ß-mercaptoethanol, 100 I.U. penicillin, and 100µg/ml streptomycin penicillin 
and streptomycin. Cells were cultured at 37°C in a humidified environment of 5% CO2 in air. 
 
Sample Collection and Preparation   
 
 INS-1 cells were scraped and pipetted to detach from the wells and centrifuged at 3000 
rpm for 5 minutes. The cell pellet was lysed by resuspending in 200 µl of lysis buffer (4% SDS, 
50 mM Tris at pH6.8) and then boiled for 6 minutes. Protein concentration was determined by 
the BCA (Sigma, St. Louis, MO) method with BSA as a standard. Samples were adjusted to 
equal protein concentration by addition of lysis buffer. Glycerol (10%), BME (5%), and 
bromophenol blue (0.025%) were added to each sample. 
 
Western Blot 
   
 Forty µg total protein aliquots from each sample were loaded onto a 10% SDS-PAGE 
(BioRad minigel) and run until the dye front reached the end of the gel. The gel was then blotted 
to nitrocellulose for 1 hour at 100V in blotting buffer (25 mM Tris, 192 mM glycine, 20% 
methanol) After blotting the nitrocellulose was dried at room temperature and then blocked 
overnight in blotto (10 mM Tris pH 8.0, 150 mM NaCl, 0.05% Tween-20, 5% nonfat dry milk) 
at 40C. The blot was then treated with rabbit polyclonal anti-Egr-1 (1:1,500, Santa Cruz, Santa 
Cruz, CA) in blotto for 1 hour at room temperature. The blot was washed 6 times (5 min/wash) 
in wash buffer (10 mM tris pH 8.0, 150 mM NaCl, 0.05% Tween-20). The blot was then 
incubated with goat anti-rabbit IgG)-HRP second antibody 1:6,700, Santa Cruz, Santa Cruz, CA) 
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for 1 hour at room temperature. The blot was then washed as previously described and reacted 
with ECL (Amersham Pharmicia Biotech Inc., Piscataway, NJ) and exposed to Hyperfilm ECL 
(Amersham Pharmicia Biotech Inc., Piscataway, NJ) for less than 10 minutes. 
 
Measurement of Nitrite and insulin   
 
 Concentrations of nitrite, a stable metabolite of nitric oxide, in the culture media were 
determined using a colorimetric procedure (Greiss Reagent). Insulin levels were determined 
using a commercially available ELISA kit (Alpco, Windham, NH).  
 
Experiment 1. Effect of Glucose on Insulin Production and Expression of Egr-1 in INS-1 
Pancreatic Beta Cells 
 
INS-1 cells were collected and plated (1 x 107 cells/well) in 6-well tissue culture plates 
and cultured in 5 ml of media for 24 hours. Culture media was aspirated and replaced with 
glucose free RPMI 1640 media (GFM) and cultured for an additonal 24 hours. Media was 
aspirated and cells were cultured in GFM supplemented with 20 mmol/L glucose, 1 mM IBMX 
and 1 µM Forskolin (GFM+) for 0, 30, 60, and 120 minutes respectively. After the appropriate 
time, media from the sample was collected and stored at -70°C for subsequent determination of 
insulin levels. Cells were collected and snap frozen for subsequent determination of Egr-1 levels 
by western blot. 
 
 
	   25	  
Experiment 2. Effect of IL-1β Treatment on Nitric Oxide Production Over Time in INS-1 Cells. 
 
INS-1 cells were collected, plated (2 x 105 cells/well) in 96-well tissue culture plates and 
cultured in 200 µl of media. After 0, 3, 6, 12, 18, and 24 hours, media was aspirated and cells 
were cultured in RPMI media alone or supplemented with 100 U/ml of IL-1β. After 0, 1, 2, 3, 6, 
9, 12, and 24 hours cells were collected, processed, and stored at -70°C for subsequent 
determination of Egr-1 protein expression by western blot. 
 
Experiment 3. Effect of IL-1β Treatment Over Time on Glucose’s Ability to Induce Egr-1 
Expression. 
 
INS-1 cells were collected and plated (1 x 107 cells/well) in 6-well tissue culture plates 
and cultured in 5 ml of media. After 24 hours, the media was aspirated and replaced with GFM 
alone or GFM supplemented with 100 U/ml IL-1β at various times following media exchange (0, 
6, 12, and 18 hours). Twenty four hours after the addition of GFM, media was aspirated and 
replaced with GFM alone or GFM supplemented with 20 mmol/L glucose, 1 mM IBMX and 1 
µM Forskolin. After 2 more hours cells were collected, processed, and stored at -70°C for 
subsequent determination of Egr-1 protein expression by western blot. 
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Experiment 4. Effect of Increasing Sodium Nitroprusside Concentrations on Glucose’s Ability to 
Induce Egr-1 Expression. 
 
 INS-1 cells were collected and plated (1 x 107 cells/well) in 6-well tissue culture plates 
and cultured in 5 ml of media. After 24 hours, media was aspirated and the cells were cultured in 
GFM for an additional 24 hours. Media was aspirated again and cells were treated with GFM 
alone, GFM supplemented with 20 mmol/L glucose, 1 mM IBMX and 1 µM Forskolin (GFM+), 
or GFM+ containing various levels of sodium nitroprusside (1.25, 2.5, 5, and 10 mM). After 2 
hours cells were collected, processed, and stored at -70°C for subsequent determination of Egr-1 
protein expression by western blot. 
 
Statistical Analyses 
 
ANOVA and pair-wise contrasts were used to test differences among time point means. 
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Results 
Experiment 1. 
 
Glucose stimulated insulin production in INS-1 cells. We examined the effect of glucose 
on insulin production in the INS-1 pancreatic beta cells. INS-1 cells were treated with glucose 
(20 mM) and cultured for 30, 60, and 120 minutes. The administration of glucose to the INS-1 
cells significantly (P<0.05) increased insulin levels at 60 (36.9 ng/ml) and 120 (51.6 ng/ml) 
minutes over that observed at time 0 (7.5 ng/ml) (Figure 2.1).   
	  
	  
Figure 2.1: Glucose significantly stimulated insulin production from INS-1 cells cultured in 
vitro at 60 and 120 minutes. Data are expressed as mean ± SEM of 3 experiments. 
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Experiment 2. 
 
Glucose increased expression of Egr-1 in INS-1 cells. We examined the effect of glucose 
on the expression of Egr-1 in INS-1 pancreatic beta cells.  INS-1 cells were treated with glucose 
(20 mM) and cultured for 30, 60, and 120 minutes. Treatment of the INS-1 cells with glucose 
significantly (P<0.05) increased the expression of Egr-1 at 60 and 120 minutes of culture as 
compared to the 0-hour time group (Figure 2.2). 	  
	  
Figure 2.2:  Effect of glucose on the expression of Egr-1 over time. Data are normalized to the 
0-minute time period which was set at 1.0. Data are expressed as mean ± SEM of 3 
experiments.  
Experiment 3. 
 Interleukin-1ß dose-dependently increases nitric oxide in INS-1 cells. We examined the 
effect of IL-1ß (0, 1, 5, 50, and 100 U/ml) on nitrite production in INS-1 pancreatic beta cells 
over time (0, 3, 6, 12, 18, and 24 hours). Administration of IL-1ß dose-dependently increased 
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nitrite production over time in the INS-1 pancreatic beta cells (Figure 2.3.). The figure also 
shows that the administration of 50 and 100 U/ml of IL-1ß increased nitrite production from 
INS-1 cells after 6 hours of culture and continued to further increase nitrite levels through 24 
hours of culture.  These data show a direct relationship between IL-1β and Nitric oxide 
production.  The time lag of six hours indicates the possibility of several intermediates in the 
pathway between IL-1β stimulation and NO production in the INS-1 pancreatic beta cells. 
	  
Figure 2.3:  Administration of IL-1β (U/ml) dose-dependently increased nitric oxide production 
from INS-1 cells cultured in vitro for 0, 3, 6, 12, 18, and 24 hours.  Data are expressed as a mean 
for each of the three experiments.    
Experiment 4. 
  Pre-treatment of INS-1 cells with IL-1ß attenuates the glucose-stimulated increase in 
Egr-1 protein expression in a time dependent manner. We examined the effect of glucose on 
Egr-1 expression in INS-1 pancreatic beta cells that had been previously treated with IL-1ß. Pre- 
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treatment of INS-1 cells with IL-1ß (100 U/ml) inhibited the glucose-induced increase in Egr-1 
protein expression in INS-1 cells cultured in vitro in a time dependent manner (Figure 2.4).  
Specifically, treatment of INS-1 cells with IL-1β for 24, 18, and 12 hours before the 
administration of glucose, significantly (p<0.05) attenuated glucose-stimulated expression of 
Egr-1 by 24, 51, and 62 percent, respectively (Figure 2.4).  In contrast, pre-treatment of INS-1 
cells with IL-1β for 6 hours before the administration of glucose did not alter glucose-stimulated 
expression of Egr-1 significantly (Figure 2.4).  This is possibly because only after 6 hours was a 
high amount of nitric oxide stimulation from IL-1β treatment of the INS-1 cells seen (Figure 
2.3).   
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Experiment 5. 
  Sodium Nitroprusside attenuates glucose-stimulation of Egr-1 expression in INS-1 cells. 
To further verify the hypothesis that IL-1ß alters glucose-stimulated expression of Egr-1 in INS-
1 cells via the upregulation of nitric oxide, we examined the effect of sodium nitroprusside, a 
nitric oxide donor, on glucose-stimulated expression of Egr-1 in INS-1 pancreatic beta cells. 
INS-1 cells were treated with glucose (20 mM) alone or in the presence of increasing 
concentrations of sodium nitroprusside (0, 1.25, 2,5, 5, and 10 mM) for 2 hours. Glucose 
significantly (p<0.05) increased the expression of Egr-1 in INS-1 pancreatic beta cells cultured 
for 2 hours (Figure 2.4).  Co-administration of sodium nitroprusside, dose-dependently, inhibited 
Figure 2.4:  Pre-treatment of INS-1 cells with IL-1ß attenuated the glucose-stimulated  
increase in Egr-1 expression in a time dependent manner. Data are normalized to the glucose  
treatment group which was set at 100%. Data are expressed as mean ± SEM for 3 experiments 
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the glucose-stimulated (P<0.05) increase in Egr-1 protein expression by INS-1 pancreatic beta 
cells cultured in vitro for 2 hours (Figure 2.5).  Administration of 2.5, 5, and 10 mM of sodium 
nitroprusside decreased the glucose-stimulated increase (P<0.05) of Egr-1 protein expression by 
15, 52, and 66 percent, respectively (Figure 2.5). 
	  
Figure 2.5: Administration of sodium nitroprusside dose-dependently inhibited glucose 
stimulation of Egr-1 expression from INS-1 cells cultured in vitro for 2 hours. Data are 
normalized to the glucose treatment group which was set at 100%. Data are expressed as mean ± 
SEM for 3 experiments. 
 
  Based on these findings we conclude that nitric oxide is an important negative regulatory 
intermediate of stimulated Egr-1 protein expression in INS-1 pancreatic beta cells.  Our findings 
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support our hypothesis that exposure of pancreatic beta cells to IL-1β initiates a cascade of 
events that subsequently alters the ability of glucose to promote normal beta cell function. 
Furthermore, our findings suggest that IL-ß’s ability to alter glucose stimulation of Egr-1 protein 
expression involves the production of nitric oxide. 
Discussion 
 
Our long-range goal is to understand the pathophysiology of IDDM and to develop new 
therapeutic strategies for prevention and/or treatment of this disease. In these studies we 
investigated the role of nitric oxide to alter the glucose-stimulated increase in the expression of 
the transcription factor, Egr-1. The importance of Egr-1 in normal beta cell function has been 
emphasized by previous reports of its role in insulin mRNA expression and its paralleled 
increase with insulin production in insulinoma cells (Frodin et al. 1995; Josefsen et al. 1999; 
Bernal-Mizrachi et al. 2001; Eto et al. 2006; Muller et al. 2012). Our observation that glucose 
stimulates the production of insulin and increases the expression of Egr-1 from cultured INS-1 
pancreatic beta cells further supports those studies. Recently, Muller et al. (2012) concluded that 
Egr proteins are import regulators of pancreatic beta cell function, influencing insulin 
biosynthesis and glucose homeostasis.  
Proinflammatory cytokines, such as IL-1ß and IFN-γ released by infiltrating immune 
cells are thought to be key mediators of apoptosis in pancreatic beta cells (Rabinovitch and 
Suarez-Pinzon 1998; Eizirik et al. 2001; Grunnet et al. 2009). Administration of IL-1ß alone, or 
in combination with IFN-γ has been shown to induce markers of apoptosis and cell death in INS-
1 cells and rat and human islets (Grunnet et al. 2009; Wu et al. 2012). Administration of IL-1ß to 
INS-1 cells significantly increased caspase-3 activity, a specific marker for apoptosis, by 7.6 fold 
over that observed in INS-1 cells cultured in media alone (Wu et al. 2012). Furthermore, Wu and 
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coworkers found that treatment of INS-1 cells with IL-1ß increased cell death by 49% over 
untreated INS-1 cells. 
 Neutralization of IL-1ß by the administration of anti-IL-1ß antibody reduced the 
incidence of cyclophosphamide-induced diabetes (34%) in non-obese diabetic (NOD) mice as 
compared to controls (100%) (Cailleau et al.1997). Similarly, administration of 0.2 mg/kg and 2 
mg/kg of a soluble IL-1 receptor to cyclophosphamide-treated NOD mice decreased the 
incidence of diabetes (53% and 7%, respectively) as compared to controls (65%). Neutralization 
of IL-1 did not alter insulitis to a great degree. These findings are consistent with the concept that 
IL-1ß is integral to the process leading to IDDM and that it likely participates in the effector 
phase because neutralization has little affect on insulitis (Rabinovitch and Suarez-Pinzon 1998). 
Collectively these findings demonstrate that proinflammatory cytokines, in particular IL-1ß, 
activate a series of events that ultimately lead to destruction of the pancreatic beta cells and onset 
of IDDM. However, the exact mechanisms activated by the release of proinflammatory cytokines 
in the pancreas, which lead to cell death, and IDDM remain to be determined. 
A detrimental compound induced by IL-1β that, in part, leads the endocrine pancreas to 
cell death and IDDM is nitric oxide (NO). Treatment of pancreatic beta cells with IL-1β has been 
shown to increase inducible nitric oxide synthase (iNOS) and thus NO concentrations (Corbett et 
al. 1991; Rabinovitch et al. 1996; Aktan 2004; Storling et al. 2005). In our studies, 
administration of IL-1ß increased nitric oxide production over time in a dose dependent manner. 
The role of nitric oxide as a key mediator of proinflammatory cytokine-induced beta cell death is 
further supported by ablation/replacement studies using pharmacological inhibitors or donors of 
nitric oxide production (Storling et al. 2005).  Rat insulinoma cells, INS-1, incubated for 24 
hours with IL-1β, IFNγ and then treated with NOS blocker NMA had a 90% reduction in 
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apoptosis (Storling et al. 2005). When a nitric oxide donor SNAP was introduced into the culture 
media of the same INS-1 cells over a 24-hour period, it dose-dependently induced apoptosis 
(Storling et al. 2005).  Kacheva et al. (2011) found similar results when treating INS-1E cells 
with an iNOS blocker. They studied the NF-κB- iNOS pathway and found an iNOS blocker 
inhibited IL-1β induced NF-κB activation.  The detrimental effect of IL-1β induced NO on the 
viability of pancreatic beta cells is suggested by these studies.   
The increased concentration of NO due to IL-1β may be causing beta cell dysfunction 
through altering transcription factor function. Transcription factors play a pivotal role in 
producing and regulating products necessary for pancreatic beta cells to function properly. They 
are strongly affected by the type of compound binding the cell whether it is glucose or pro-
inflammatory cytokines, such as IL-1β. The importance of Egr-1 in pancreatic beta cell health 
and function is supported in a number of studies (Frodin et al. 1995; Josefsen et al. 1999; Bernal-
Mizrachi et al. 2000; Garnett et al. 2005; Eto et al. 2006; Muller et al. 2012).  It participates in 
these positive functions through glucose stimulation (Josefsen et al. 1999; Eto et al. 2006; Muller 
et al. 2012). NO production inhibits normal pathways enacted by glucose including insulin 
secretion (Corbett et al. 1993; Tsuura et al. 1998; Henningsson et al. 2002). Henningsson et al. 
(2002) treated mouse islets with 20mM of glucose for 60 minutes and found exogenous or 
endogenous NO donors suppressed insulin secretion but increased it dramatically with nitric 
oxide inhibitors.  One target of NO in the glucose pathway that has been identified is 
phosphofruktokinase (Tsuura et al. 1998).  Another target of NO is the zinc finger transcription 
factor Egr-1 (Henderson et al. 1994; Kroncke et al. 2001). Interference of glucose stimulated 
Egr-1 via IL-1β induced NO production could play an important part in IDDM development.   
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A number of studies using pharmacological donors of NO, including the present study, 
suggests NO plays an important role in IDDM development through Egr-1. We found sodium 
nitroprusside, a NO donor, dose dependently inhibited glucose induced Egr-1 production. 
Henderson et al. (1994) treated rat lung macrophages with low doses of NO donor SNAP (0.1-
1mM), before treatment with IFN and LPS and found a decrease in Egr-1 transcription by 70%. 
A study treating glomerular mesangial cells (MC) with S-nitrosoglutathione (GSNO) suppressed 
Egr-1 binding sites and ultimately inhibited MC proliferation (-84%) (Rupprecht et al. 2000). 
Kroncke et al. (2001) found treatment of recombinant Egr-1 with NO donor S-nitrosocysteine 
(SNOC) dose-dependently inhibited DNA binding by the transcription factor.   
The role of IL-1β induced NO in pancreatic beta cell death is not fully understood.  It is 
widely recognized as playing a large part in beta cell destruction. Our studies confirmed that IL-
1β increased NO levels beginning at the 6-hour marker. This time frame coordinated with the 
time it took for IL-1β to begin inhibiting glucose induced Egr-1 production.  These 2 studies 
show that IL-1β interferes with glucose’s ability to function normally in part through inhibition 
of Egr-1. In order to confirm that it was nitric oxide and not another compound, we treated the 
INS-1 cells with increasing concentrations of SNP and found Egr-1 was inhibited dose-
dependently. This reconfirms previous studies suggesting NO directly affects Egr-1 expression. 
Our study has shown that IL-1β alters glucose’s ability to induce Egr-1 production through NO. 
Our findings provide evidence for the first time that the increase in nitric oxide in pancreatic beta 
cells during the onset of IDDM may alter the ability of glucose to promote cell viability and 
inhibit insulin production, therefore leaving the cells more susceptible to cell death. 	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APPENDICES 
APPENDIX A 
Cell Processing Cell	  Lysis	  Buffer	  10%	  SDS	   	   	   	   	   	   	   	   	  	  	  4ml	  	   1M	  Tris-­‐HCL,	  6.8pH	   	   	   	   	   	   	   500µl	  	   diH2O	   	   	   	   	   	   	   	   	   5.5ml	  	   	   	   	   	   	   	   	   	   	   	  10ml	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APPENDIX B 
 
Protein Assay 	  Diluted	  Albumin(BSA)	  Standards:	  Thermo	  Scientific	  BCATM	  Protein	  Assay	  Kit	  Vial	   Volume	  of	  Diluent	   Volume	  &	  Sourcoe	  of	  BSA	   Final	  BSA	  Concentration	  A	   0µl	   300µl	  of	  stock	   2000µg/ml	  B	   125µl	   375µl	  of	  stock	   1500µg/ml	  C	   325µl	   325µl	  of	  stock	   1000µg/ml	  D	   175µl	   175µl	  of	  vial	  B	  dilution	   750µg/ml	  E	   325µl	   325µl	  of	  vial	  C	  dilution	   500µg/ml	  F	   325µl	   325µl	  of	  vial	  E	  dilution	   250µg/ml	  G	   325µl	   325µl	  of	  vial	  F	  dilution	   125µg/ml	  H	   400µl	   100µl	  of	  vial	  G	  dilution	   25µg/ml	  I	   400µl	   0	   0µg/ml=Blank	  	  	   	   	   	   	   	   	   	   	   	   	  BCA	  Working	  Reagent:	  	   BCA	  Reagent	  A	  (50	  parts)	  +	  Reagent	  B	  (1	  part)	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